Lakefront Biotherapeutics
€25.66Change from previous close: −0.23%Absolute change: −€0.06
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- €1.68B
- Enterprise value
- -€544.54M
- P/E (trailing 12 months)
- 2.84
- Forward P/E
- -5.18
- Price/book
- 0.52
- Price/sales
- 1.70
- EV/EBITDA
- -0.96
- EV/revenue
- -0.55
Profitability and growth
- Gross margin
- 67.6%
- Operating margin
- -359.3%
- Net margin
- 60.2%
- ROE
- 20.1%
- ROA
- 9.9%
- Revenue growth (year over year)
- -81.5%
Financial health
- Total cash
- €2.24B
- Total debt
- €6.36M
- Debt/equity
- 0.00
- Current ratio
- 32.8
- Quick ratio
- 32.6
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- €31.46
- Median price target
- €30.00
- High price target
- €44.80
- Low price target
- €19.00
- Analysts with a price target
- 7
- Forward EPS
- -€4.95
- EPS estimate, current year
- -€1.89
Shares and trading
- Beta
- 0.12
- Average volume
- 93.59K
- Shares outstanding
- 65.48M
- Float
- 23.72M
- Institutional ownership
- 43.1%
- Insider ownership
- 25.4%